Monocyte Targeting Technology

Monocytes are key drivers of the inflammatory process and maintain the chronic stage in various inflammatory diseases.
Monocytes are a type of immune cell that forms in the bone marrow and travel through the blood to inflamed tissues.

VBL has developed its Monocyte Targeting Technology (MTT), as an investigational new and specific way to limit chronic inflammation. Our program is based on the discovery of a novel target protein that is selectively expressed on the surface of monocytes and controls their ability to migrate (or 'walk' to) inflamed tissues. This protein is called MOSPD2 (the "mono-walk" receptor).

Our lead MTT candidate, VB-601, is an investigational proprietary monoclonal antibody that binds the MOSPD2 ("mono-walk") receptor and is engineered to specifically prevent monocytes from exiting the blood stream and traveling to inflamed tissues. VB-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents, most of which target pro-inflammatory molecules and work through T and B lymphocytes but are not targeted to the monocyte cells.

VB-601 aims to offer a novel and differentiated mechanism to treat inflammation:

Several drugs target & inhibit T cell or B cell mediated immune response, but the inflammation persists.

The Problem

There is no treatment targeting monocytes, key immune cells controlling the inflammatory response.

Our Solution

VB-601 is designed to uniquely target monocytes and prevent their movement to sites of inflammation, thereby potentially restraining the inflammatory process.

VB-601 is an antibody that binds circulating monocytes and blocks their ability to exit the blood and migrate to inflammatory tissues. Mobility of B or T cells is not affected.

VBL intends to initiate a first-in-human study of VB-601 in the second half of 2022.

Based on our pre-clinical and human ex-vivo data, we believe VB-601 has potential utility in a wide range of immune-inflammatory diseases, such as multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, non-alcoholic steatohepatitis (NASH), inflammatory bowel disease and other immune-inflammatory diseases.

Frequently Asked Questions